Products & Targets

Product

‍

PN-900 CandidaGenius® C. auris screening assay (50 rxn)  

Target

• Candida auris

‍

Features & benefits

• To detect and identify Candida auris DNA after nucleic acid extraction from noninvasive swabs
• Direct identification from ESwab - no culturing required
• Targets the ITS gene to determine the presence of Candida auris
• Results in under 1.5 hours
• Compatible with multiple PCR instruments
• Internal Control included
• Positive Control included

‍

Real-time PCR instruments

• LightCycler 480 II (Roche)
• Rotor-Gene Q (Qiagen)
• CFX96 (Biorad)
• Quantstudio 5 (Thermo Fisher Scientific)
• Mic qPCR cycler (Bio Molecular Systems)

‍

Specimen

• ESwabs from nares, mouth/throat, perineum, bilateral axillae and groin

‍

Quality

• For Research Use Only (RUO)
• Not for use in clinical diagnostic procedures

‍

Background

Candida auris has emerged as a formidable global health threat due to its multi-drug resistance. First identified in Japan in 2009, Candida auris has now been isolated in over 40 countries worldwide. Frequent misdiagnosis, high mortality rates and its ability to survive in the environment led to Candida auris being listed as a critical priority pathogen by the WHO in 2022.

‍Candidemia, a bloodstream infection caused by Candida auris, is particularly severe, with mortality rates reaching as high as 72%. Asymptomatic carriers or colonized patients can unknowingly spread the fungus, especially in hospitals and nursing homes, where it can survive on surfaces for 2 weeks to 7 months.

As the incidence of Candida auris steadily increases and considering its difficulty to diagnose, treat and eradicate, the need for effective screening implementation is evident. Molecular methods, which are both sensitive and specific, would allow for an easy, low-cost and accurate way to identify Candida auris in a clinical setting.

‍

‍